Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and ...

In this article, we take a look at five biotech companies developing potentially transformative medicines to treat cystic ...

We think Casgevy's high selling price and the significant unmet medical need for treating sickle cell disease and transfusion-dependent beta-thalassemia will help it become a blockbuster drug during ...

Vertex Pharmaceuticals beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday.Please watch the video at Investors.com - How To Buy ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment ...

Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

Coming off of a strong third quarter, Vertex Pharmaceuticals is nearing several important milestones, including the potential approvals of vanzacaftor triple in cystic fibrosis and the non-opioid ...